

LAHIVE
&
COCKFIELD

LLP

COUNSELLORS AT LAW
28 STATE STREET
BOSTON, MASSACHUSETTS 02109-1784
TELEPHONE (617) 227-7400
FAX (617) 742-4214
lc@lahcoc.com



Assistant Commissioner for Patents
Box Sequence
Washington, DC 20231

JOHN A. LAHIVE, JR. (1928-1997)
THOMAS V. SMURZYNSKI
RALPH A. LOREN
GIULIO A. DeCONTI, JR.
ANN LAMPORT HAMMITTE
ELIZABETH A. HANLEY
AMY BAKER MANDRAGOURAS
ANTHONY A. LAURENTANO
KEVIN J. CANNING
JANE E. REMILLARD
JEANNE M. DIGIORGIO
DEBRA J. MILASINCIC, Ph.D.
NICHOLAS P. TRIANO, III
WILLIAM D. DEVAUL

CHI SUK KIM
DAVID J. RIKKERS
DAVID R. BURNS
JOHN S. CURRAN
SEAN D. DETWEILER

SENIOR COUNSEL
JAMES E. COCKFIELD

OF COUNSEL
JEREMIAH LYNCH
WILLIAM A. SCOFIELD, JR.
PETER C. LAURO *
DeANN FORAN SMITH**

* Admitted in NY only
** Admitted in MI only
*** Passed the Patent Bar Examination

RECEIVED
SEP 20 2000
GAR 1632
PATENT AGENTS
MEGAN E. WILLIAMS, Ph.D.

TECH CENTER 1600/2900
TECHNICAL SPECIALISTS
MARIA LACCOTRIPE ZACHARAKIS, Ph.D.***
CYNTHIA M. SOROS
PETER W. DINI, Ph.D.
LAUREN C. FOSTER, D.Sc.
EUIHOON LEE
ERICK B. BERGLUND, Ph.D.
LISA M. DIROCCO
JENNIFER K. ROSENFIELD
JUDITH STONE-HULSLANDER, Ph.D.
PETER S. STECHER

RECEIVED
SEP 20 2000
TECH CENTER 1600/2900

August 29, 2000

Re: U.S. Divisional Application Serial No.: 09/206,132
Entitled: *Tumor Cells Modified To Express B7-2 With Increased Immunogenicity And Uses Therefor*
Inventors: Gordon J. Freeman, Lee M. Nadler and Gary S. Gray
Filed: December 7, 1998
Attorney Docket No.: RPI-008CPDV

Dear Sir:

I enclose herewith for filing in the above-identified application the following:


1. Letter Regarding Diskette Containing Sequence Listing (in duplicate);
2. Copy of Notice to Comply;
3. Copy of Divisional-Continuation Application Transmittal Form Under Rule 1.53(b) (former Rule 1.60) mailed on December 7, 1998; and
4. A Prepaid Return Postcard.

Please charge any necessary fees to our Deposit Account No. 12-0080. The undersigned requests any extensions of time necessary to respond. A duplicate of this sheet is enclosed.

I hereby certify that this correspondence is deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Box Sequence, Washington, DC 20231 on:

August 29, 2000

Date


Megan E. Williams, Ph.D., Reg. No.43,270

Respectfully submitted,

LAHIVE & COCKFIELD, LLP


Megan E. Williams, Ph.D.
Reg. No. 43,270

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Gordon J. Freeman, Lee M. Nadler and
Gary S. Gray

Serial No.: 09/206,132

Filed: December 7, 1998

For: Tumor Cells Modified to Express B7-2 with Increased
Immunogenicity and Uses Therefor


Attorney Docket No.: RPI-008CPDV

Assistant Commissioner for Patents
Box Sequence
Washington, D.C. 20231

Group Art Unit: 1632

Examiner: K Hauda

RECEIVED
#9 Linda
SEP 20 2000 10/11/00
TECH CENTER 1600/2900



LETTER REGARDING DISKETTE CONTAINING SEQUENCE LISTING

Dear Sir:

Pursuant to the requirements of §1.821(e), I hereby state that in accordance with the requirements of §1.824(d), a diskette containing a computer readable form of the Sequence Listing was filed in the pending prior application serial no 08/456,104 filed on May 30, 1995. The material on this diskette was identical in substance to the Sequence Listing appearing on pages 33-47 of the instant specification. Applicants note that this information was provided in item number 12 of the Divisional-Continuation Application Transmittal Form Under Rule 1.53(b) (former Rule 1.60) filed with the U.S. Patent and Trademark Office on December 7, 1998. Accordingly, no new matter has been added.

No fees are believed to be due in connection with this communication. If, however, additional fees are due, please charge any necessary fees or credit any overpayments to our Deposit Account No. 12-0080. For this purpose, a duplicate of this sheet is enclosed.

Certificate of First Class Mailing (37 CFR 1.8(a))

I hereby certify that this correspondence is deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Box Sequence, Washington, DC 20231 on:

August 29, 2000

Date

Megan E. Williams, Ph.D., Reg. No. 43,270

Respectfully submitted,

Megan E. Williams, Ph.D.
Reg. No. 43,270
LAHIVE & COCKFIELD, LLP
28 State Street
Boston, MA 02109
(617) 227-7400

Dated: August 29, 2000



Application No.: 09/206,132

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.

2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).

3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).

4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."

5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).

6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).

7. Other: _____

Applicant Must Provide:

An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".

An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.

A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For PatentIn software help, call (703) 308-6856


PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE

Customer Number: 000959

DIVISIONAL-CONTINUATION APPLICATION TRANSMITTAL FORM
UNDER RULE 1.53(b) (former Rule 1.60)

DOCKET NUMBER	ANTICIPATED CLASSIFICATION OF THIS APPLICATION:		PRIOR APPLICATION SERIAL NUMBER: 08/456,104	PRIOR APPLICATION FILING DATE: MAY 30, 1995
RPI-008CPDV	CLASS:	SUBCLASS:	EXAMINER:	ART UNIT:

ASSISTANT COMMISSIONER FOR PATENTS
 BOX PATENT APPLICATION
 WASHINGTON, DC 20231



CERTIFICATION UNDER 37 CFR 1.10

Date of Deposit: December 7, 1998 Mailing Label Number: EL094330961US

I hereby certify that this 37 CFR 1.53(b) request and the documents referred to as attached therein are being deposited with the United States Postal Service on the date indicated above in an envelope as "Express Mail Post Office to Addressee" service under 37 CFR 1.10 and addressed to the Assistant Commissioner for Patents, Box Patent Application, Washington, D.C. 20231.

Virato G. Cardoso
 Name of Person Mailing Paper

Virato G. Cardoso
 Signature of Person Mailing Paper

Dear Sir:

This is a request for filing a continuation divisional application under 37 CFR 1.53(b), of pending prior application serial no. 08/456,104 filed on May 30, 1995 of Gordon J. Freeman, Lee M. Nadler and Gary S. Gray entitled Tumor Cells Modified To Express B7-2 With Increased Immunogenicity And Uses Therefor.

1. Enclosed is a copy of the latest inventor signed application, including the oath or declaration as originally filed. The copy of the enclosed papers is as follows:
 - 47 page(s) of specification
 - 7 page(s) of claims
 - 1 page(s) of abstract
 - 2 sheet(s) of drawing
 - page(s) of declaration and power of attorney.

I hereby verify that the attached papers are a true copy of the prior complete application serial no. 08/456,104 as originally filed on May 30, 1995.

2. The filing fee is calculated below:

	NUMBER OF CLAIMS FILED	MINUS	NUMBER EXTRA
TOTAL	44	** 20	= 24
INDEP.	8	MINUS *** 3	= 5
<input type="checkbox"/> MULTIPLE DEPENDENT CLAIMS			

SMALL ENTITY

RATE	FEES
x 9 =	\$0.00
x 39 =	\$0.00
+130 =	\$0.00
BASIC FEE	\$0.00
TOTAL	\$0.00

OTHER THAN A SMALL ENTITY

OR	RATE	FEES
x 18 =	\$432.00	
x 78 =	\$390.00	
+ 260 =	\$0.00	
BASIC FEE	\$760.00	
TOTAL	\$1582.00	

3. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Deposit Account No. . A duplicate copy of this sheet is enclosed.

4. Cancel in this application original claims 1-41, 44, and 45 of the prior application before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)
5. A preliminary amendment is enclosed. (Claims added by this amendment have been properly numbered consecutively beginning with the number next following the highest numbered original claims in the prior application.)
6. Transfer the drawings from the pending prior application to this application.
7. The prior application is assigned of record to Dana-Farber Cancer Institute and Repligen Corporation.
8. The power of attorney in the prior application is to Lahive & Cockfield, LLP.
 - a. The power appears in the original papers in the prior application.
 - b. Since the power does not appear in the original papers, a copy of the power in the prior application is enclosed.
 - c. A new power has been executed and is attached.
9. A copy of An Associate Power of Attorney in USSN: 08/456,104 to Megan E. Williams is enclosed.
10. Address all future communications (May only be completed by applicant, or attorney or agent of record) to Amy E. Mandragouras at **Customer Number: 000959** whose address is:

Lahive & Cockfield, LLP
28 State Street
Boston, Massachusetts 02109

11. Any requests for extensions of time necessary in a parent application for establishing copendency between this application and a parent application are hereby requested and the Commissioner is authorized to charge any fee associated with such an extension to Deposit Account No. 12-0080.
12. Pursuant to 37 CFR 1.821(e), the computer readable form of the sequence listing for this new application is to be identical with the computer readable form of application serial no. 08/456,104. Please use the computer readable form of application serial no. 08/456,104 in lieu of filing a duplicate computer readable form in this application. Pursuant to 37 CFR 1.821(f), the content of the paper copy of the sequence listing for this new application and the computer readable form of application serial no. 08/456,104 are the same.

December 7, 1998
Date

LAHIVE & COCKFIELD, LLP
28 State Street
Boston, Massachusetts 02109
Tel. (617) 227-7400



Megan E. Williams, Ph.D.
Reg. No. 43,270
 inventor(s) filed under § 1.34(a)
 assignee of complete interest
 attorney or agent of record